Neogen ChemicalsQ1 FY27
Neogen Chemicals Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹2,125P/E: 171.7Market Cap: ₹6.1K CrSector: Chemicals & Petrochemicals
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- →Base business revenue expected to cross INR 1,000 crore in FY27 with 10-15% growth projected for FY28, targeting INR 1,100-1,200 crore.
- →Optimization focus in FY28 on margins, working capital, and product mix, emphasizing larger volume molecules to improve efficiency.
- →Battery chemicals business anticipated to reach INR 300 crore revenue in FY27, mainly from salts (~INR 200 crore) and electrolyte (~INR 100 crore).
- →FY28 battery chemicals revenue expected to exceed INR 1,000 crore with 70-80% salt utilization and 30-50% electrolyte utilization.
- →By FY29, full capacity utilization is targeted for both base and battery businesses, potentially generating INR 2,400-2,900 crore revenue from local electrolyte and international salt business.
- →Working capital cycle expected to improve from 140-160 days to 110-120 days as business scales and larger molecules dominate.
- →Continuous growth with focus on operational optimization and working capital efficiencies from FY28 onwards.
Margin guidance
Category 3- →**Revenue Growth**: Base business expected to grow from INR 950-1,050 crore in FY27 to INR 1,100-1,200 crore in FY28, with 10-15% increase focused on stabilizing and optimizing operations.
- →**Battery Chemicals**: Strong growth anticipated; revenues projected to exceed INR 1,000 crore in FY28 driven by increased utilization in salt and electrolyte production.
- →**Working Capital & Cash Flow**: Working capital cycle to improve from 140-160 days towards 90 days in battery business by FY29, enhancing cash flow.
- →**Profitability & Margins**: EBITDA margins expanding (19.3% in Q1 FY27); cost pass-through and optimized product mix supporting margin growth.
- →**Cash Flow Conversion**: Structural enhancements expected to push operating cash flow conversion to about 70% of EBITDA by FY29.
- →**Debt Management**: Peak debt targeted between INR 1,000-1,500 crore post-capex, with INR 600 crore QIP aiding deleveraging and lowering finance costs (~INR 40-50 crore savings annually).
- →**Long-term Outlook**: FY29 marked as key year with full utilization, optimized margins, positive operating cash flow, and improved free cash flow potential.
3 more insights locked — sign up free to unlock
Fundraise plans
Yes- →The company has approved a proposed QIP fundraise of up to INR 600 crore, primarily aimed at debt reduction and providing financial flexibility for future growth opportunities, including battery material supply chain initiatives and international market expansion.
- →The INR 600 crore QIP proceeds are expected to lower finance costs by roughly INR 40-50 crore annually, depending on the actual repayment amount and future investment needs.
- →The INR 1,800 crore battery chemical CAPEX is being funded via a combination of already drawn debt, equity from the Morita JV (around INR 30-40 crore remaining), and remaining debt drawdown.
- →Neogen Morita has been authorized to borrow an additional INR 500 crore, which is mainly a shift of planned loans from Neogen Ionics and not an increase in total debt.
- →Peak consolidated debt post-raising the QIP and completing CAPEX is targeted between INR 1,000 to 1,500 crore, down from earlier estimates of INR 1,800 crore net debt.
Order book
- →The salt business for the current year is backed by long-term formula-based pricing contracts linked to lithium carbonate pricing, with firm orders already in place.
- →All four global customers have audited and approved Neogen's facility.
- →Customers are expected to start purchasing gradually in Q2 and Q3 FY27, with full supply from Neogen expected towards the end of Q3 and into Q4.
- →Interim sales during Q2-Q3 may include some special pricing, but from Q4 onwards, pricing will follow the contracted formula.
- →The contracts are designed to provide stable, consistent pricing rather than fluctuating spot prices.
- →No explicit orderbook value is given, but the firm contracted volumes are expected to support 70-80% utilization capacity for salt business in FY27.
Capex plans
Yes- →Neogen Ionics battery chemical CAPEX planned at INR 1,800 crore, with INR 1,300 crore already spent; remaining INR 500 crore expected by FY27 end.
- →Incremental CAPEX partly debt-funded and partly equity from Morita (around INR 40-50 crore equity remaining).
- →Additional CAPEX for salt and additive capacities planned: 2,000-ton salt capacity at Pakhajan and 500-ton additive capacity at Dahej, requiring ~15 months to build plus approvals.
- →Potential capacity ramp-up in organo-lithium segment with minor CAPEX (<INR 15 crore) expected in second half of current year after Board approval.
- →Future CSM business capacity expansion possible from FY29-FY30, post clarity on Dahej plant performance.
- →INR 600 crore QIP fundraise approved primarily for debt reduction and to fund future growth opportunities, including battery materials and meeting international demand.
- →Continuous R&D investment planned for battery performance improvements with novel additives and electrolyte designs.
How does Neogen Chemicals rank vs peers in Chemicals & Petrochemicals?
Pro feature1Neogen Chemicals
Rev 2Mar 3
See full Chemicals & Petrochemicals sector rankings
How does Neogen Chemicals rank in Chemicals & Petrochemicals?
Compare Neogen Chemicals against every Chemicals & Petrochemicals company (Q1 FY27) on revenue, margins and earnings-call signals.